Evidence map›Paper›PMID 42017894›Full record

ArticleHuman vaccines & immunotherapeutics2026

Estimating the age distribution of disease-causal HPV infection in women with high-grade cervical intraepithelial neoplasia in Denmark, Estonia, Norway, Slovenia, and Sweden: A modeling study.

Ugne Sabale, Alhaji Cherif, Stefano Valente, John Cook, Manisha Yadav, Gargi Baluni, Marta Del Pino, Andrea Marcellusi, Xuedan You

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ugne SabaleValue & Implementation Outcomes Research, MSD, Vilnius, Lithuania.ORCID 0000-0003-1874-8730
Alhaji CherifHealth Economic and Decision Sciences, Merck & Co., Inc., Rahway, NJ, USA.ORCID 0000-0001-8654-2772
Stefano ValenteValue & Implementation Global Medical and Scientific Affairs, MSD, Rome, Italy.
John CookEconomic Modeling and Adaptations, Peritia, Morrisville, NC, USA.ORCID 0000-0001-8758-8326
Manisha YadavEconomic Modeling and Adaptations, Peritia, Morrisville, NC, USA.ORCID 0009-0006-1364-8684
Gargi BaluniEconomic Modeling and Adaptations, Peritia, Morrisville, NC, USA.ORCID 0009-0008-2484-7739
Marta Del PinoInstitute Clinic of Gynecology, Obstetrics, and Neonatology, Hospital Clínic, Universitat de Barcelona, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Andrea MarcellusiDepartment of Pharmaceutical Sciences (DISFARM), Università degli Studi di Milano, Milan, Italy.
Xuedan YouValue & Implementation Outcomes Research, Merck & Co., Inc., Rahway, NJ, USA.ORCID 0000-0002-2551-9111

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The age distribution of disease-causal human papillomavirus (HPV) infections that lead to high-grade cervical intraepithelial neoplasia (CIN2+) is not well understood in Europe. The objective of this study was to estimate the age at acquisition of disease-causal HPV infection in women diagnosed with CIN2+ in Denmark, Estonia, Norway, Slovenia, and Sweden. A previously published discrete event simulation model was modified to estimate the age of disease-causal HPV infection for females diagnosed with CIN2+ by comparing predicted and observed age distributions of CIN2+ diagnoses using a chi-square goodness-of-fit test. Scenario and sensitivity analyses were also performed. The predicted median age (years) of disease-causal HPV infection was 23.69 in Denmark, 26.73 (narrow case definition for CIN2+ diagnosis) and 28.34 (broad definition) in Estonia, 29.32 in Norway, 32.03 in Slovenia, and 26.33 in Sweden. The percentage of women aged over 26 and 45 years with a predicted causal HPV infection was 42.7%/8.1% (26/45 years) in Denmark, 52.8%/9.0% (narrow definition) and 57.9%/12.7% (broad definition) in Estonia, 64.7%/11.9% in Norway, 72.3%/21.4% in Slovenia, and 51.2%/9.4% in Sweden. Model results were robust to variations in inputs and parametrization tested in scenario and sensitivity analyses. A considerable proportion (42.7-72.3%) of causal HPV infections are projected to occur in women over age 26, while 8.1%-21.4% are projected to occur in women over the age of 45. These findings highlight a need to consider HPV vaccination for previously unvaccinated women to reduce the burden of CIN2+ and cervical cancer.

Indexed as

Papillomavirus InfectionsUterine Cervical DysplasiaUterine Cervical NeoplasmsAdolescentAdultAgedAge DistributionEuropeFemaleHuman Papillomavirus VirusesHumansMiddle AgedYoung Adultadultcancerdisease-causal HPV infectionhigh-grade cervical intraepithelial neoplasiaHuman papillomavirusvaccination

Identifiers

PMID42017894
PMCPMC13108347

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.